Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-12-2018 | Review

Viral infection and atherosclerosis

Authors: Nima Hemmat, Amin Ebadi, Reza Badalzadeh, Mohammad Yousef Memar, Hossein Bannazadeh Baghi

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 12/2018

Abstract

Several risk factors have been described for the pathogenesis of atherosclerosis. Infectious diseases are suggested to be a causative factor, and some viruses have been studied for their relation with atherosclerotic diseases. Studies report two hypotheses, direct and indirect effects, for the role of viral infections in atherogenesis. Viruses are able to initiate atherosclerosis by two different pathways. They can exert their direct effects on atherogenesis by infecting vascular cells and then inducing inflammation in the endothelium and smooth muscle cells. Alternatively, they can also apply indirect effects by infecting non-vascular cells and inducing systemic inflammation. In this review, we consider the available data about the effects and correlations of DNA and RNA viruses on atherosclerosis.

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F, Centers for Disease C, Prevention, American Heart A (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3):499–511. https://doi.org/10.1161/01.CIR.0000052939.59093.45 CrossRefPubMed

Merz CNB, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, Hodgson TK, Matthews KA, Pepine CJ, Reis SE (2003) Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol 41(3):413–419. https://doi.org/10.1016/S0735-1097(02)02763-8 CrossRef

O’Connor S, Taylor C, Campbell LA, Epstein S, Libby P (2001) Potential infectious etiologies of atherosclerosis: a multifactorial perspective. Emerg Infect Dis 7(5):780–788. https://doi.org/10.3201/eid0705.010503 CrossRefPubMedPubMedCentral

Campbell LA, Rosenfeld ME (2015) Infection and atherosclerosis development. Arch Med Res 46(5):339–350. https://doi.org/10.1016/j.arcmed.2015.05.006 CrossRefPubMedPubMedCentral

Danesh J, Collins R, Peto R (1997) Chronic infections and coronary heart disease: is there a link? Lancet 350(9075):430–436. https://doi.org/10.1016/S0140-6736(97)03079-1 CrossRefPubMed

Libby P, Egan D, Skarlatos S (1997) Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 96(11):4095–4103. https://doi.org/10.1161/01.CIR.96.11.4095 CrossRefPubMed

Mattila K, Valtonen V, Nieminen MS, Asikainen S (1998) Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 26(3):719–734. https://doi.org/10.1086/514570 CrossRefPubMed

Estein S, Zhou Y, Zhu J (1999) Infection and atherosclerosis: emerging mechanism paradigms. Circulation 100:e20–e28

Hajjar DP (1991) Warner-Lambert/Parke-Davis Award Lecture. Viral pathogenesis of atherosclerosis. Impact of molecular mimicry and viral genes. Am J Pathol 139(6):1195–1211PubMedPubMedCentral

10.

Fabricant CG, Fabricant J (1999) Atherosclerosis induced by infection with Marek’s disease herpesvirus in chickens. Am Heart J 138(5):S465–S468. https://doi.org/10.1016/S0002-8703(99)70276-0 CrossRefPubMed

11.

Benditt EP, Barrett T, McDougall JK (1983) Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A 80(20):6386–6389. https://doi.org/10.1073/pnas.80.20.6386 CrossRefPubMedPubMedCentral

12.

Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17(11):1410–1422. https://doi.org/10.1038/nm.2538 CrossRef

13.

Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE (2001) Cytomegalovirus infection increases development of atherosclerosis in apolipoprotein-E knockout mice. Atherosclerosis 156(1):23–28. https://doi.org/10.1016/S0021-9150(00)00608-0 CrossRefPubMed

14.

Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA (1990) High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 136(1):23–28PubMedPubMedCentral

15.

Chiu B, Viira E, Tucker W, Fong IW (1997) Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 96(7):2144–2148. https://doi.org/10.1161/01.CIR.96.7.2144 CrossRefPubMed

16.

Horváth R, Černý J, Benedík JRJ, Hökl J, Jelínková I, Benedík J (2000) The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. J Clin Virol 16(1):17–24. https://doi.org/10.1016/S1386-6532(99)00064-5 CrossRefPubMed

17.

Burnett MS, Gaydos CA, Madico GE, Glad SM, Paigen B, Quinn TC, Epstein SE (2001) Atherosclerosis in apoE knockout mice infected with multiple pathogens. J Infect Dis 183(2):226–231. https://doi.org/10.1086/317938 CrossRefPubMed

18.

Vliegen I, Duijvestijn A, Stassen F, Bruggeman C (2004) Murine cytomegalovirus infection directs macrophage differentiation into a pro-inflammatory immune phenotype: implications for atherogenesis. Microbes Infect 6(12):1056–1062. https://doi.org/10.1016/j.micinf.2004.05.020 CrossRefPubMed

19.

Etingin OR, Silverstein RL, Hajjar DP (1991) Identification of a monocyte receptor on herpesvirus-infected endothelial cells. Proc Natl Acad Sci U S A 88(16):7200–7203. https://doi.org/10.1073/pnas.88.16.7200 CrossRefPubMedPubMedCentral

20.

Chirathaworn C, Pongpanich A, Poovorawan Y (2004) Herpes simplex virus 1 induced LOX-1 expression in an endothelial cell line, ECV 304. Viral Immunol 17(2):308–314. https://doi.org/10.1089/0882824041310531 CrossRefPubMed

21.

Hajjar DP, Pomerantz KB, Falcone DJ, Weksler BB, Grant AJ (1987) Herpes simplex virus infection in human arterial cells. Implications in arteriosclerosis. J Clin Invest 80(5):1317–1321. https://doi.org/10.1172/JCI113208 CrossRefPubMedPubMedCentral

22.

Shi Y, Tokunaga O (2002) Herpesvirus (HSV-1, EBV and CMV) infections in atherosclerotic compared with non-atherosclerotic aortic tissue. Pathol Int 52(1):31–39. https://doi.org/10.1046/j.1440-1827.2002.01312.x CrossRefPubMed

23.

Sutherland MR, Raynor CM, Leenknegt H, Wright JF, Pryzdial EL (1997) Coagulation initiated on herpesviruses. Proc Natl Acad Sci U S A 94(25):13510–13514. https://doi.org/10.1073/pnas.94.25.13510 CrossRefPubMedPubMedCentral

24.

Sun Y, Pei W, Wu Y, Jing Z, Zhang J, Wang G (2004) Herpes simplex virus type 2 infection is a risk factor for hypertension. Hypertens Res 27(8):541–544. https://doi.org/10.1291/hypres.27.541 CrossRefPubMed

25.

Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, Schlumberger W, Meyer J, AtheroGene I (2002) Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation 105(1):15–21. https://doi.org/10.1161/hc0102.101362 CrossRefPubMed

26.

Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, Hafner G, Prellwitz W, Schlumberger W, Meyer J (2002) Impact of infectious burden on progression of carotid atherosclerosis. Stroke 33(11):2581–2586. https://doi.org/10.1161/01.STR.0000034789.82859.A4 CrossRefPubMed

27.

KOTRONIAS D, KAPRANOS N (2005) Herpes simplex virus as a determinant risk factor for coronary artery atherosclerosis and myocardial infarction. In Vivo 19(2):351–357PubMed

28.

Ibrahim AI, Obeid MT, Jouma MJ, Moasis GA, Al-Richane WL, Kindermann I, Boehm M, Roemer K, Mueller-Lantzsch N, Gartner BC (2005) Detection of herpes simplex virus, cytomegalovirus and Epstein-Barr virus DNA in atherosclerotic plaques and in unaffected bypass grafts. J Clin Virol 32(1):29–32. https://doi.org/10.1016/j.jcv.2004.06.010 CrossRefPubMed

29.

De Backer J, Mak R, De Bacquer D, Van Renterghem L, Verbraekel E, Kornitzer M, De Backer G (2002) Parameters of inflammation and infection in a community based case-control study of coronary heart disease. Atherosclerosis 160(2):457–463. https://doi.org/10.1016/S0021-9150(01)00602-5 CrossRefPubMed

30.

Liu SC, Tsai CT, Wu CK, Yu MF, Wu MZ, Lin LI, Wang SS, Hwang JJ, Tseng YZ, Chiang FT, Tseng CD (2009) Human parvovirus b19 infection in patients with coronary atherosclerosis. Arch Med Res 40(7):612–617. https://doi.org/10.1016/j.arcmed.2009.09.002 CrossRefPubMed

31.

Kerr JR, Barah F, Mattey DL, Laing I, Hopkins SJ, Hutchinson IV, Tyrrell DA (2001) Circulating tumour necrosis factor-alpha and interferon-gamma are detectable during acute and convalescent parvovirus B19 infection and are associated with prolonged and chronic fatigue. J Gen Virol 82(Pt 12):3011–3019. https://doi.org/10.1099/0022-1317-82-12-3011 CrossRefPubMed

32.

Lawson JS, Glenn WK, Tran DD, Ngan CC, Duflou JA, Whitaker NJ (2015) Identification of human papilloma viruses in atheromatous coronary artery disease. Front Cardiovasc Med 2:17. https://doi.org/10.3389/fcvm.2015.00017 CrossRefPubMedPubMedCentral

33.

Bonin LR, Madden K, Shera K, Ihle J, Matthews C, Aziz S, Perez-Reyes N, McDougall JK, Conroy SC (1999) Generation and characterization of human smooth muscle cell lines derived from atherosclerotic plaque. Arterioscler Thromb Vasc Biol 19(3):575–587. https://doi.org/10.1161/01.ATV.19.3.575 CrossRefPubMed

34.

Tong DY, Wang XH, Xu CF, Yang YZ, Xiong SD (2005) Hepatitis B virus infection and coronary atherosclerosis: results from a population with relatively high prevalence of hepatitis B virus. World J Gastroenterol 11(9):1292–1296. https://doi.org/10.3748/wjg.v11.i9.1292 CrossRefPubMedPubMedCentral

35.

Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C (2007) Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 46(6):1126–1132. https://doi.org/10.1016/j.jhep.2007.01.021 CrossRefPubMed

36.

Nikolopoulou A, Tousoulis D, Antoniades C, Petroheilou K, Vasiliadou C, Papageorgiou N, Koniari K, Stefanadi E, Latsios G, Siasos G, Stefanadis C (2008) Common community infections and the risk for coronary artery disease and acute myocardial infarction: evidence for chronic over-expression of tumor necrosis factor alpha and vascular cells adhesion molecule-1. Int J Cardiol 130(2):246–250. https://doi.org/10.1016/j.ijcard.2007.08.052 CrossRefPubMed

37.

Zhu J, Quyyumi AA, Norman JE, Costello R, Csako G, Epstein SE (2000) The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. J Infect Dis 182(6):1583–1587. https://doi.org/10.1086/317613 CrossRefPubMed

38.

Costantini S, Capone F, Guerriero E, Maio P, Colonna G, Castello G (2010) Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. Eur Cytokine Netw 21(4):251–256. https://doi.org/10.1684/ecn.2010.0214 CrossRefPubMed

39.

Petta S, Torres D, Fazio G, Camma C, Cabibi D, Di Marco V, Licata A, Marchesini G, Mazzola A, Parrinello G, Novo S, Licata G, Craxi A (2012) Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology 55(5):1317–1323. https://doi.org/10.1002/hep.25508 CrossRefPubMed

40.

Oliveira CP, Kappel CR, Siqueira ER, Lima VM, Stefano JT, Michalczuk MT, Marini SS, Barbeiro HV, Soriano FG, Carrilho FJ, Pereira LM, Alvares-da-Silva MR (2013) Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol 164(2):221–226. https://doi.org/10.1016/j.ijcard.2011.07.016 CrossRefPubMed

41.

Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, Zoli M, Melchionda N (1999) Cardiovascular disease in cirrhosis—a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 94(3):655–662. https://doi.org/10.1111/j.1572-0241.1999.00931.x CrossRefPubMed

42.

Auer J, Leitinger M, Berent R, Prammer W, Weber T, Lassnig E, Eber B (2002) Influenza A and B IgG seropositivity and coronary atherosclerosis assessed by angiography. Heart Dis 4(6):349–354. https://doi.org/10.1097/01.HDX.0000038560.97526.1D CrossRefPubMed

43.

Naghavi M, Wyde P, Litovsky S, Madjid M, Akhtar A, Naguib S, Siadaty MS, Sanati S, Casscells W (2003) Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation 107(5):762–768. https://doi.org/10.1161/01.CIR.0000048190.68071.2B CrossRefPubMed

44.

Van Lenten BJ, Wagner AC, Anantharamaiah G, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM (2002) Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein AI mimetic peptide. Circulation 106(9):1127–1132. https://doi.org/10.1161/01.CIR.0000030182.35880.3E CrossRefPubMed

45.

Kearns A, Gordon J, Burdo TH, Qin X (2017) HIV-1-associated atherosclerosis: unraveling the missing link. J Am Coll Cardiol 69(25):3084–3098. https://doi.org/10.1016/j.jacc.2017.05.012 CrossRefPubMedPubMedCentral

46.

D'Ascenzo F, Cerrato E, Calcagno A, Grossomarra W, Ballocca F, Omedè P, Montefusco A, Veglia S, Barbero U, Gili S (2015) High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis 240(1):197–204. https://doi.org/10.1016/j.atherosclerosis.2015.03.019 CrossRefPubMed

47.

Sosner P, Wangermez M, Chagneau-Derrode C, Le Moal G, Silvain C (2012) Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis 222(1):274–277. https://doi.org/10.1016/j.atherosclerosis.2012.02.027 CrossRefPubMed

48.

Duffy P, Wang X, Lin PH, Yao Q, Chen C (2009) HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial Cells1. J Surg Res 156(2):257–264. https://doi.org/10.1016/j.jss.2009.02.005 CrossRefPubMedPubMedCentral

49.

Kwon TW, Kim DK, Ye JS, Lee WJ, Moon MS, Joo CH, Lee H, Kim YK (2004) Detection of enterovirus, cytomegalovirus, and Chlamydia pneumoniae in atheromas. J Microbiol 42(4):299–304PubMed

50.

Guan XR, Jiang LX, Ma XH, Wang LF, Quan H, Li HY (2010) Respiratory syncytial virus infection and risk of acute myocardial infarction. Am J Med Sci 340(5):356–359. https://doi.org/10.1097/MAJ.0b013e3181eecf29 CrossRefPubMed

51.

Layegh P, Shoeibi A, Nikkhah K, Juibary AG, Raftari S, Darbarpanah S, Boroumand R, Azarpazhooh M (2014) Can HTLV-1 infection be a potential risk factor for atherosclerosis? Intervirology 57(6):365–368. https://doi.org/10.1159/000365785 CrossRefPubMed

52.

Leinonen M, Saikku P (2002) Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect Dis 2(1):11–17. https://doi.org/10.1016/S1473-3099(01)00168-2 CrossRefPubMed

53.

Alber DG, Powell KL, Vallance P, Goodwin DA, Grahame-Clarke C (2000) Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation 102(7):779–785. https://doi.org/10.1161/01.CIR.102.7.779 CrossRefPubMed

54.

Rosenfeld ME, Campbell LA (2011) Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 106(5):858–867. https://doi.org/10.1160/TH11-06-0392 CrossRefPubMed

55.

Jiang B, Hebert VY, Khandelwal AR, Stokes KY, Dugas TR (2009) HIV-1 antiretrovirals induce oxidant injury and increase intima-media thickness in an atherogenic mouse model. Toxicol Lett 187(3):164–171. https://doi.org/10.1016/j.toxlet.2009.02.017 CrossRefPubMedPubMedCentral

56.

Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE (1989) Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. Jama 261(24):3561–3566. https://doi.org/10.1001/jama.1989.03420240075030 CrossRefPubMed

57.

Wang Z, Cai J, Zhang M, Wang X, Chi H, Feng H, Yang X (2016) Positive expression of human cytomegalovirus phosphoprotein 65 in atherosclerosis. Biomed Res Int 2016:4067685. https://doi.org/10.1155/2016/4067685 CrossRefPubMedPubMedCentral

58.

Daus H, Ozbek C, Saage D, Scheller B, Schieffer H, Pfreundschuh M, Gause A (1998) Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation. Cardiology 90(2):83–88. https://doi.org/10.1159/000006824 CrossRefPubMed

59.

Saetta A, Fanourakis G, Agapitos E, Davaris PS (2000) Atherosclerosis of the carotid artery; absence of evidence for CMV involvement in atheroma formation. Cardiovasc Pathol 9(3):181–183. https://doi.org/10.1016/S1054-8807(00)00040-5 CrossRefPubMed

60.

Bason C, Corrocher R, Lunardi C, Puccetti P, Olivieri O, Girelli D, Navone R, Beri R, Millo E, Margonato A, Martinelli N, Puccetti A (2003) Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet 362(9400):1971–1977. https://doi.org/10.1016/S0140-6736(03)15016-7 CrossRefPubMed

61.

Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, Tamassia N, Tinazzi E, Beri R, Corrocher R, Puccetti A (2007) Endothelial cells’ activation and apoptosis induced by a subset of antibodies against human cytomegalovirus: relevance to the pathogenesis of atherosclerosis. PLoS One 2(5):e473. https://doi.org/10.1371/journal.pone.0000473 CrossRefPubMedPubMedCentral

62.

Zhang J, Liu Y-Y, Sun H-L, Li S, Xiong H-R, Yang Z-Q, Xiang G-D, Jiang X-J (2015) High human cytomegalovirus IgG level is associated with increased incidence of diabetic atherosclerosis in type 2 diabetes mellitus patients. Med Sci Monit 21:4102. https://doi.org/10.12659/MSM.896071 CrossRefPubMedPubMedCentral

63.

Malkin JE (2004) Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 11(Suppl 1):2A–23APubMed

64.

Hechter RC, Budoff M, Hodis HN, Rinaldo CR, Jenkins FJ, Jacobson LP, Kingsley LA, Taiwo B, Post WS, Margolick JB (2012) Herpes simplex virus type 2 (HSV-2) as a coronary atherosclerosis risk factor in HIV-infected men: multicenter AIDS cohort study. Atherosclerosis 223(2):433–436. https://doi.org/10.1016/j.atherosclerosis.2012.03.002 CrossRefPubMedPubMedCentral

65.

Young LS, Rickinson AB (2004) Epstein–Barr virus: 40 years on. Nat Rev Cancer 4(10):757–768. https://doi.org/10.1038/nrc1452 CrossRefPubMed

66.

Lobzin Iu V, Boitsov SA, Filippov AE, Linchak RM, Mangutov DA (2005) Effect of respiratory infections on the clinical course of coronary artery disease. Klin Med (Mosk) 83(11):22–26

67.

Takahashi M, Ito M, Sakamoto F, Shimizu N, Furukawa T, Takahashi M, Matsunaga Y (1995) Human parvovirus B19 infection: immunohistochemical and electron microscopic studies of skin lesions. J Cutan Pathol 22(2):168–172. https://doi.org/10.1111/j.1600-0560.1995.tb01402.x CrossRefPubMed

68.

Nakazawa T, Tomosugi N, Sakamoto K, Asaka M, Yuri T, Ishikawa I, Kitagawa S (2000) Acute glomerulonephritis after human parvovirus B19 infection. Am J Kidney Dis 35(6):E31. https://doi.org/10.1016/S0272-6386(00)70070-9 CrossRefPubMed

69.

Kuo H-K, Fujise K (2011) Human papillomavirus and cardiovascular disease among US women in the National Health and Nutrition Examination Survey, 2003 to 2006. J Am Coll Cardiol 58(19):2001–2006. https://doi.org/10.1016/j.jacc.2011.07.038 CrossRefPubMed

70.

Foresta C, Bertoldo A, Garolla A, Pizzol D, Mason S, Lenzi A, De Toni L (2013) Human papillomavirus proteins are found in peripheral blood and semen Cd20+ and Cd56+ cells during Hpv-16 semen infection. BMC Infect Dis 13(1):593. https://doi.org/10.1186/1471-2334-13-593 CrossRefPubMedPubMedCentral

71.

Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336(14):973–979. https://doi.org/10.1056/NEJM199704033361401 CrossRefPubMed

72.

Berk BC, Weintraub WS, Alexander RW (1990) Elevation of C-reactive protein in “active” coronary artery disease. Am J Cardiol 65(3):168–172. https://doi.org/10.1016/0002-9149(90)90079-G CrossRefPubMed

73.

Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331(7):417–424. https://doi.org/10.1056/NEJM199408183310701 CrossRefPubMed

74.

Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332(10):635–641. https://doi.org/10.1056/NEJM199503093321003 CrossRefPubMed

75.

Kuller LH, Tracy RP, Shaten J, Meilahn EN (1996) Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 144(6):537–547. https://doi.org/10.1093/oxfordjournals.aje.a008963 CrossRefPubMed

76.

Amirzadegan A, Davoodi G, Boroumand M, Darabyan S, Dehkordi M, Goodarzynejad H (2007) Association between hepatitis B surface antibody seropositivity and coronary artery disease. Indian J Med Sci 61(12):648CrossRef

77.

Ghotaslou R, Aslanabadi N, Ghojazadeh M (2008) Hepatitis B virus infection and the risk of coronary atherosclerosis. Ann Acad Med Singap 37(11):913–915PubMed

78.

Sung J, Song YM, Choi YH, Ebrahim S, Davey Smith G (2007) Hepatitis B virus seropositivity and the risk of stroke and myocardial infarction. Stroke 38(5):1436–1441. https://doi.org/10.1161/STROKEAHA.106.466268 CrossRefPubMed

79.

Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, Loria P, Florio A (2012) Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis 221(2):496–502. https://doi.org/10.1016/j.atherosclerosis.2012.01.051 CrossRefPubMed

80.

Majumdar M, Ratho RK, Chawla Y, Singh MP (2015) Role of TLR gene expression and cytokine profiling in the immunopathogenesis of viral hepatitis E. J Clin Virol 73:8–13. https://doi.org/10.1016/j.jcv.2015.09.011 CrossRefPubMed

81.

Madjid M, Awan I, Ali M, Frazier L, Casscells W (2005) Influenza and atherosclerosis: vaccination for cardiovascular disease prevention. Expert Opin Biol Ther 5(1):91–96. https://doi.org/10.1517/14712598.5.1.91 CrossRefPubMed

82.

Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A (2011) Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 32(14):1730–1735. https://doi.org/10.1093/eurheartj/ehr004 CrossRefPubMed

83.

Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W (2000) Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 102(25):3039–3045. https://doi.org/10.1161/01.CIR.102.25.3039 CrossRefPubMed

84.

Heffelfinger JD, Heckbert SR, Psaty BM, Weiss NS, Thompson WW, Bridges CB, Jackson LA (2006) Influenza vaccination and risk of incident myocardial infarction. Hum Vaccin 2(4):161–166. https://doi.org/10.4161/hv.2.4.2943 CrossRefPubMed

85.

Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, Thompson WW (2002) Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol 156(7):634–640. https://doi.org/10.1093/aje/kwf073 CrossRefPubMed

86.

Guan XR, Li X, Xin XM, Jiang LX, Cui LY, Wang LF, Li HY (2008) Influenza virus infection and risk of acute myocardial infarction. Inflammation 31(4):266–272. https://doi.org/10.1007/s10753-008-9074-2 CrossRefPubMed

87.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte A, Phillips AN, Sabin CA, Lundgren JD, Group DADS (2014) Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 384(9939):241–248. https://doi.org/10.1016/S0140-6736(14)60604-8 CrossRefPubMed

88.

Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, Nasir K, Grinspoon SK (2010) Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 24(2):243–253. https://doi.org/10.1097/QAD.0b013e328333ea9e CrossRefPubMedPubMedCentral

89.

Zanni MV, Abbara S, Lo J, Wai B, Hark D, Marmarelis E, Grinspoon SK (2013) Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS 27(8):1263–1272. https://doi.org/10.1097/QAD.0b013e32835eca9b CrossRefPubMedPubMedCentral

90.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, Monforte AA, Pradier C, Morfeldt L, Mateu S, Law M (2003) Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. Aids 17(8):1179–1193. https://doi.org/10.1097/01.aids.0000060358.78202.c1 CrossRefPubMed

91.

Hansson GK, Robertson AK, Soderberg-Naucler C (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1:297–329. https://doi.org/10.1146/annurev.pathol.1.110304.100100 CrossRefPubMed

Title: Viral infection and atherosclerosis
Authors: Nima Hemmat
Amin Ebadi
Reza Badalzadeh
Mohammad Yousef Memar
Hossein Bannazadeh Baghi
Publication date: 01-12-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 12/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-018-3370-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2018

A systematic review of randomised clinical trials for oral antibiotic treatment of acute pyelonephritis

How are trainees in clinical microbiology and infectious diseases supervised in Europe? An international cross-sectional questionnaire survey by the Trainee Association of ESCMID

Variable spectrum of disease and risk factors of peripartum Clostridium difficile infection: report of 14 cases from French hospitals and literature review

Novel diagnostic ELISA test for discrimination between infections with Yersinia enterocolitica and Yersinia pseudotuberculosis

Roles of intestinal microbiota in response to cancer immunotherapy

Real-time quantitative PCR analysis of endoscopic biopsies for diagnosing CMV gastrointestinal disease in non-HIV immunocompromised patients: a diagnostic accuracy study

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage